36 completed, 13 recruiting, 9 terminated, 6 withdrawn. 70 Phase 2, 23 Phase 1, 2 Phase 3.
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm Exploratory Study Lanoracopan, Anti-thymocyte globulin (ATG), Calcineurin inhibitor (Cyclosporine or Tacrolimus) - Hematologic Malignancies, Haploidentical Peripheral Blood Stem Cell Transplantation | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-12-01 | 2026-11-09 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-14 | 2026-11-13 |
| Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention Cyclophosphamide (primary intervention for GVHD prophylaxis) - Graft-versus-Host Disease (GVHD), Hematologic Malignancies | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 41 | 2026-03-09 | 2026-04-03 |
| The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation Thiotepa, Fludarabine, G-CSF - Hematologic Malignancies | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 44 | 2026-02-20 | 2026-03-02 |
| A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant Cyclophosphamide, Mycophenolate Mofetil, Ruxolitinib - Hematologic Malignancies | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-01-20 | 2026-07-07 |
| PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) PUL-042, Placebo - Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT) | Phase 2 | Recruiting | Pulmotect, Inc. | 100 | 2025-06-27 | 2026-08-04 |
| Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation Drugs Cyclophosphamide, Fludarabine, Thiotepa - Hematologic Malignancies | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 35 | 2025-03-03 | 2026-04-28 |
| Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients Leflunomide 20 mg - Hematologic Malignancies | Phase 2 | Recruiting | Tata Memorial Centre | 22 | 2024-10-18 | 2026-07-16 |
| IVIG for Infection Prevention After CAR-T-Cell Therapy Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline - Hematologic Malignancies | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 150 | 2024-06-10 | 2026-06-29 |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) ICP-248, Orelabrutinib - Hematologic Malignancies | Phase 2 / Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 226 | 2024-05-15 | 2025-11-21 |
| Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Fludarabine, Melphalan, Total Body Irradiation - Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation | Phase 2 | Recruiting | University of California, Irvine | 60 | 2023-09-11 | 2026-02-02 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... RIC, GVHD prophylaxis, allo HCT - HIV, Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 265 | 2023-01-26 | 2026-11-09 |
| Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab Tafasitamab - Hematologic Malignancies | Phase 2 | Recruiting | Incyte Corporation | 25 | 2022-11-08 | 2025-12-10 |
| A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies CN202 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Unknown | Curon Biopharmaceutical (Australia) Co Pty Ltd | 164 | 2021-10-22 | 2021-08-31 |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML SLS009, venetoclax, azacitidine - Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | Sellas Life Sciences Group | 160 | 2021-05-10 | 2026-09-03 |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Nemtabrutinib - Hematologic Malignancies, Waldenstroms Macroglobulinaemia | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 490 | 2021-04-05 | 2026-10-27 |
| A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma Teclistamab - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Janssen Pharmaceutical K.K. | 40 | 2021-02-22 | 2026-06-05 |
| Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease Tildrakizumab - Hematologic Malignancies | Phase 2 | Completed | Medical College of Wisconsin | 51 | 2020-03-01 | 2025-10-21 |
| Therapy for Progressive and/or Refractory Hematologic Malignancies TAPA-pulsed DC vaccine - Cancer, Hematologic Malignancies | Phase 1 / Phase 2 | Withdrawn | Kiromic BioPharma Inc. | 2017-07-28 | 2018-08-28 |
Showing 20 of 70. Sign in to see all of them.
Hematologic Neoplasms (70) · Graft vs Host Disease (12) · Myelodysplastic Syndromes (11) · Leukemia (9) · Lymphoma, Non-Hodgkin (9) · Hodgkin Disease (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Leukemia, Myeloid, Acute (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma (7) · Multiple Myeloma (6) · Myeloproliferative Disorders (4) · Neoplasms (4) · Neoplasms, Plasma Cell (4)
Hemic and Lymphatic Diseases (70) · Neoplasms by Site (70) · Hematologic Diseases (67) · Neoplasms (66) · Immune System Diseases (30) · Neoplasms by Histologic Type (23) · Immunoproliferative Disorders (20) · Lymphoproliferative Disorders (20) · Lymphatic Diseases (19) · Pathological Conditions, Signs and Symptoms (15) · Bone Marrow Diseases (14) · Pathologic Processes (14) · Disease Attributes (13) · Leukemia, Lymphoid (11) · Chronic Disease (10)
Tacrolimus (15) · fludarabine (15) · Cyclophosphamide (11) · Whole-Body Irradiation (10) · Mycophenolic Acid (9) · fludarabine phosphate (7) · Busulfan (6) · Melphalan (5) · Thiotepa (5) · Methotrexate (4) · Sirolimus (4) · Stem Cell Transplantation (4) · Rituximab (3) · Antilymphocyte Serum (2) · Azacitidine (2)
Dana-Farber Cancer Institute (3) · M.D. Anderson Cancer Center (3) · Merck Sharp & Dohme LLC (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · A.O. Ospedale Papa Giovanni XXIII (2) · Fate Therapeutics (2) · Kiromic BioPharma Inc. (2) · Masonic Cancer Center, University of Minnesota (2) · National Cancer Institute (NCI) (2) · Tarix Pharmaceuticals (2) · Accenture (1) · Anne Beaven, MD (1) · Baylor College of Medicine (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Celgene (1)
United States (51) · Italy (7) · Spain (5) · Germany (4) · South Korea (4) · Canada (3) · China (3) · Hungary (3) · Israel (3) · United Kingdom (3) · Australia (2) · France (2) · Turkey (Türkiye) (2) · Argentina (1) · Austria (1)
Neal Flomenberg, MD (2) · Patrick Stiff, MD (2) · Agha Mounzer, MD (1) · Alberto Bosi, MD (1) · Alessandro AR Rambaldi, Professor (1) · Alessandro Rambaldi, MD (1) · Alexandra Gomez Arteaga, MD (1) · Amelia Langston, MD (1) · Amer M Beitinjaneh, MD (1) · Amr Qudeimat, MD (1) · Anne Beaven, MD (1) · Attaphol Pawarode, M.D. (1) · Caitlin Caitlin, MD (1)
PMID 10515382, PMID 10573044, PMID 12659416, PMID 15528753, PMID 15845896, PMID 16115130, PMID 16732175, PMID 16980990, PMID 17162214, PMID 17606446, PMID 18307672, PMID 18451242, PMID 18468541, PMID 18703664, PMID 18820709, PMID 19462317, PMID 19713456, PMID 19955306, PMID 20350611, PMID 20685246, PMID 20837781, PMID 21393326, PMID 21417678, PMID 21868572, PMID 22093814, PMID 22491731, PMID 23065508, PMID 23146063, PMID 23524640, PMID 24295572, PMID 25075128, PMID 25790744, PMID 25949314, PMID 26869630, PMID 27047808, PMID 27418009, PMID 27682069, PMID 28544502, PMID 28986189, PMID 29190347, PMID 29211658, PMID 29242852, PMID 29477778, PMID 31054984, PMID 31135970, PMID 31153807, PMID 31217161, PMID 32017805, PMID 32202631, PMID 34305463
2023 (2), 2009 (1), 2025 (1), P01CA015396 (1), P01CA065493 (1), R01CA276040 (1)